7. Timothy Ring - C.R. Bard

2014 pay: $10.8 million
2015 pay: $11.7 million

A couple years ago, C.R. Bard ($BCR) CEO Timothy Ring revealed a strategic investment plan to drive the company toward growth. Under Ring’s stewardship, the company delivered on that plan in 2015 with a 3% increase in revenue.

With recent progress under its belt, C.R. Bard is concentrating on “investing in areas of faster growth” to provide shareholders with “sustainable attractive returns,” Ring said in the company’s Q4 2015 earnings statement. Deals could be on the horizon, especially as the company’s competitors turn to M&A to gain ground on rivals.

But that’s not to say that Bard isn’t facing its share of problems. The company is dealing with vaginal mesh lawsuits and suffered some stinging losses in 2015. In November, Bard announced that it would shell out $3.6 million in damages in the first case that went to trial over its transvaginal mesh implants. The company had already agreed to settle thousands of suits from women who claimed injury from related products.

Ring’s 2015 pay included a $1 million base salary, $4.6 million in stock awards, $2.7 million in options and $1.7 million in non-equity incentives.

- here’s C.R. Bard’s proxy statement

For more:
Bard loses bid to delay vaginal mesh trial proceedings
C.R. Bard forks over $3.6M in first case to go to trial over vaginal mesh implant

7. Timothy Ring - C.R. Bard

Suggested Articles

Inotrem and Roche’s diagnostics division have upgraded their years-long collaboration on a plasma test for septic shock, with a new worldwide deal.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.